The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines

Melanoma Research

Volumn 19, Issue 5, 2009, Pages 283-293

  Valiahdi, Seied Mojtaba ^a   Heffeter, Petra ^b   Jakupec, Michael A ^a   Marculescu, Rodrig ^c,d   Berger, Walter ^b   Rappersberger, Klemens ^d   Keppler, Bernhard K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Clinical Institute of Medical   (Austria)

^d KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Apoptosis; Cell cycle arrest; Chemotherapy; Cytotoxicity; Gallium; Human Tumor Cloning Assay

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; FOTEMUSTINE; GALLIUM; KP 46; TRIS(8 QUINOLINOLATO) GALLIUM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; DNA DAMAGE; DNA STRUCTURE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; GALLIUM; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; ORGANOMETALLIC COMPOUNDS; OXYQUINOLINE;

EID: 73349096008     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832b272d     Document Type: Article

References (33)

1. Van der Wall H, McLaughlin AF, Southee AE. Gallium scintigraphy in tumor diagnosis and management. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. Vol.2. 2nd ed. Edinburgh: Churchill Livingston; 1998. pp. 813-829.
2. Kirkwood JM, Myers JE, Vlock DR, Neumann R, Ariyan S, Gottschalk A, et al. Tomographic gallium-67 citrate scanning: useful new surveillance for metastatic melanoma. Ann Intern Med 1982; 97:694-699.
3. Kagan R,Witt T, Bines S, Mesleh G, Economou S. Gallium-67 scanning for malignant melanoma. Cancer 1988; 61:272-274.
4. Straus DJ. Gallium nitrate in the treatment of lymphoma. Semin Oncol 2003; 30 (Suppl 5):25-33.
5. Einhorn L. Galium nitrate in the treatment of bladder cancer. Semin Oncol 2003; 30 (Suppl 5):34-41.
6. Hedley DW, Tripp EH, Slowiaczek P, Mann GJ. Effect of gallium on DNA synthesis by human T-cell lymphoblasts. Cancer Res 1988; 48:3014-3018.
7. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, O'Brien WJ. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 1988; 72:1930-1936.
8. Bernstein LR. Mechanisms of therapeutic activity for gallium. Pharmacol Rev 1998; 50:665-682.
9. Chitambar CR. Apoptotic mechanisms of gallium nitrate: basic and clinical investigations. Oncology 2004; 18 (Suppl 10):39-44.
10. Casper ES, Stanton GF, Sordillo PP, Parente R, Michaelson RA, Vinceguerra V. Phase II trial of gallium nitrate in patients with advanced malignant melanoma. Cancer Treat Rep 1985; 69:1019-1020.
11. Collery P, Keppler B, Madoulet C, Desoize B. Gallium in cancer treatment. Crit Rev Oncol Hematol 2002; 42:283-296.
12. Thiel M, Schilling T, Gey DC, Ziegler R, Collery P, Keppler BK. Tris(8-quinolinolato)gallium(III), a novel orally applied antitumor gallium compound. Contrib Oncol 1999; 54:439-443.
13. Jakupec MA, Heffeter P, Pongratz M, Fremuth M, Horvath Z, Unfried P, et al. Depletion of cellular dNTP pools, cell cycle arrest and apoptosis induced by the oral gallium complex KP46 (FFC11). Clin Cancer Res 2005; 11 (24 Suppl):9159s.
14. Hofheinz RD, Dittrich C, Jakupec MA, Drescher A, Jaehde U, Gneist M, et al. Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors - a CESAR study (Central European Society for Anticancer Drug Research - EWIV). Int J Clin Pharmacol Ther 2005; 43:590-591.
15. Collery P, Domingo JL, Keppler BK. Preclinical toxicity and tissue gallium distribution of a novel antitumour gallium compound: tris(8-quinolinolato)gallium(III). Anticancer Res 1996; 16:687-692. (Pubitemid 126501648)
16. Dhara SC. A rapid method for the synthesis of cis-[Pt(NH3)2Cl2]. Indian J Chem 1970; 8:192-193.
17. Shealy YF, Krauth CA, Montgomery JA. Imidazoles. I. Coupling Reactions of 5-Diazoimidazole-4-carboxamide. J Org Chem 1962; 27:2150-2154.
18. BergerW, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M. Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 1997; 71:108-115. (Pubitemid 27158417)
19. Dornetshuber R, Heffeter P, Kamyar MR, Peterbauer T, Berger W, Lemmens-Gruber R. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. Chem Res Toxicol 2007; 20:465-473.
20. Elbling L, Berger W, Weiss RM, Printz D, Fritsch G, Micksche M. A novel bioassay for P-glycoprotein functionality using cytochalasin D. Cytometry 1998; 31:187-198.
21. Dittrich C. Cloning of solid tumors. Wien: Springer; 1987.
22. Heffeter P, Jakupec MA, Körner W,Wild S, Keyserlingk N Graf von, Elbling L, et al. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772; FFC24). Biochem Pharmacol 2006; 71:426-440.
23. Zorbas-Seifried S, Jakupec MA, Kukushkin NV, Groessl M, Hartinger CG, Semenova O, et al. Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands. Mol Pharmacol 2007; 71:357-365.
24. Valiahdi SM, Jakupec MA, Marculescu R, Keppler BK. Tris(8-quinolinolato) gallium(III) exerts strong antiproliferative effects in melanoma cells. Metal Ions Biol Med 2006; 9:282-286.
25. Jakupec MA, Keppler BK. Gallium and other main group metal compounds as antitumor agents. In: Sigel A, Sigel H, editors. Metal ions in biological systems. Vol.42. New York: M. Dekker; 2004. pp. 425-462.
26. Dumontet C, Jaubert J, Sebban C, Bouafia F, Ardiet C, Tranchand B, et al. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Ann Oncol 2003; 14:615-622.
27. Collery P, Lechenault F, Cazabat A, Juvin E, Khassanova L, Evangelou A, Keppler B. Inhibitory effects of gallium chloride and tris(8-quinolinolato) gallium III on A549 human malignant cell line. Anticancer Res 2000; 20:955-958.
28. Hanauske AR, Von Hoff DD. In vitro and in vivo predictive tests. In: Holland JF, Frei E, Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, editors. Cancer medicine. Hamilton: B. C. Decker; 2000. pp. 585-588.
29. Meyskens FL, Loescher L, Moon TE, Takasugi B, Salmon SE. Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. J Clin Oncol 1984; 2:1223-1228.
30. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983; 43:1926-1931.
31. Collery P, Jakupec MA, Kynast B, Keppler BK. Preclinical and early clinical development of the antitumor gallium complex KP46 (FFC11). Metal Ions Biol Med 2006; 9:521-524.
32. Chitambar CR, Wereley JP, Matsuyama S. Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol Cancer Ther 2006; 5:2834-2843.
33. Jakupec MA, Collery P, Keppler BK. Synergistic antiproliferative effects of tris(8-quinolinolato)gallium(III) (KP46) in combination with platinum drugs in ovarian and colon carcinoma cells. Metal Ions Biol Med 2008; 10:110-115.